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Alterations in the formation and metabolism of brady-
kinin (Bk) are hypothesized to play a role in the patho-
physiology of hypertension, atherosclerosis and vascular 
complications of diabetes. However, despite its promi-
nent role in cardiovascular regulation, studies on brady-
kinin have been limited by various difficulties in accurate 
measurements of this peptide in biological samples. In 
this study, using the LC-ESI-MS method we estimated 
the conversion of exogenous Bk to its main metabolites 
— Bk-(1–5) and Bk-(1–7) — in endothelial cell culture 
and in fragments of aorta of normotensive (WKY) and 
hypertensive rats (SHR). The effects of angiotensin con-
verting enzyme (ACE) and neutral endopeptidase (NEP) 
inhibitors were more pronounced in SHR: perindoprilat 
inhibited Bk-(1–5) formation by 49  % and 76  % in WKY 
and SHR rats, respectively, and tiorphan tended to de-
crease formation of Bk-(1–5) in both groups of animals. 
The degradation of bradykinin and generation of both 
metabolites were significantly higher in the aorta of SHR 
rats than in WKY controls. Our results show that even in 
relatively early hypertension (in 4-month old SHR rats) 
inactivation of Bk by aorta wall is enhanced. 
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INTRODUCTION
Bradykinin (Bk) is a small peptide involved in a va-
riety of cardiovascular effects, e.g., endothelium-depen-
dent vasodilatation (by stimulation of endothelial nitric 
oxide, prostacyclin and endothelial hyperpolarizing fac-
tor release), natriuresis, cardioprotection and regulation 
of smooth muscle cell proliferation. Alterations in the 
formation and/or metabolism of Bk are hypothesized 
to play a role in the pathophysiology of hypertension, 
atherosclerosis and vascular complications of diabetes 
(Mombouli & Vanhoutte, 1995; Erdos Marcic, 2001; 
Bryant & Shariat-Madar, 2009; Sharma, 2009). However, 
despite the prominent role of Bk in cardiovascular regu-
lation, its studies have been limited by various difficulties 
in accurate measurements of this peptide in biological 
samples: the concentrations of Bk in plasma or extra-
cellular fluid are very low and its half-life is very short 
(17 s) (Ferreira & Vane, 1967). Moreover, with its rapid 
degradation, it is reasonable to assume that the vascular 
action of Bk occurs mostly locally and tracking its me-
tabolism within the vessel wall seems more relevant than 
measurements done in the plasma (Campbell et al., 1993; 
Mombouli & Vanhoutte, 1995; Erdos & Deddish, 2002). 
It is known that Bk is rapidly cleaved by various proteas-
es to yield several products — mainly Bk-(1–5) and Bk-
(1–7) — in this regard collectively called kininases, and 
that angiotensin converting enzyme (ACE) shows high 
kininase activity (Fig. 1) (Campbell et al., 1993; Bryant 
& Shariat-Madar, 2009). It has also been demonstrated 
that increased Bk bioavilability represents an important 
mechanism of beneficial cardiovascular actions of ACE 
inhibitors (ACEi) (Tom et al., 2002). Notably, overactiva-
tion of the renin-angiotensin system is a hallmark of hy-
pertension (Ramírez-Expósito & Martínez-Martos, 2008). 
Thus, the aim of our study was to determine the vascu-
lar metabolism of bradykinin in hypertension. 
Recently, we developed an LC-ESI-MS method for in 
vitro and ex vivo study of angiotensin metabolism in vari-
ous rat tissues (Bujak-Gizycka et al., 2007; Olszanecki et 
al., 2009). Here, we adapted this method to compare the 
metabolism of Bk to its main metabolites, Bk-(1–5) and 
Bk-(1–7) in aortas of normotensive and hypertensive rats 
and to assess Bk degradation in a culture of endothelial 
cells.
MATERIALS AND METHODS
Animals. Male Wistar-Kyoto rats (WKY, n=5) and 
spontaneously hypertensive rats (SHR, n=5) at 4 months 
of age and 230–270 g of weight were kept under con-
trolled conditions (temperature, humidity and 12 h/12 h 
light/dark cycle), with a free access to food and water. 
Animals were administered fraxiparine (2850 IU, i.p.) 
and anaesthetized with 50 mg of thiopentone (50 mg/
ml, i.p.). Fragments of aorta were excised through ab-
dominal incision. All procedures were approved by the 
Ethical Committee of the Jagiellonian University.
Preparation of aorta fragments and organ-bath 
procedure. Tissue fragments were washed with cold 
standard Krebs-Henseleit solution (glucose 10 mM, py-
ruvate 2 mM, Hepes 10 mM, EDTA 0.03 mM, NaCl 
118 mM, KCl 4.7 mM, CaCl2 2.5 mM, KH2PO4 1.2 
mM, MgSO4 1.2 mM, NaHCO3 15 mM) and cleaned 
of thrombi and tissue remnants. Blood vessels were cut 
into a suitable number of rings and opened flat. Tissue 
fragments were incubated before further procedures for 
30 min at 37 °C in Krebs-Henseleit solution continuously 
bubbled with 95  % O2/5 % CO2.
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Abbreviations: ACE, angiotensin converting enzyme; ACE2, angi-
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VEC, human umbilical vein endothelial cells; NEP, neprilysin, mem-
brane-bound neutral endopeptidase; POP, prolyloligopeptidase
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Aorta fragments were individually transferred into 
Eppendorf tubes filled with 0.4 ml of bubbled Krebs-
Henseleit solution at 37 °C. Sample of 50 μl of buffer 
was removed to provide information on background 
production of Bk metabolites. Subsequently, 50 μl of 
Krebs-Henseleit solution or perindoprilat or tiorphan (to 
achieve a final concentration of 10 μM) were added to 
each tube. After another 5 min of incubation, Bk was 
added to a final concentration of 100 nM. After 15 min-
utes a second sample of 50 μl of incubation buffer was 
removed. Each sample was promptly frozen at –70 °C 
until further analysis with mass spectrometry. Tissue 
samples were dried overnight at 60 °C to allow estima-
tion of bradykinin metabolite production per mg of dry 
tissue.
Cell culture experiments. Hybridoma EA.hy926 
cell line, formed by the fusion of HUVEC with the hu-
man lung carcinoma cell line A549 was kindly provided 
by Dr. C-J. Edgell (Department of Pathology, Univer-
sity of North Carolina, Chapel Hill, NC, USA) (Edgell 
et al., 1990). EA.hy926 cells were cultured in Dulbecco’s 
modified Eagle medium (DMEM) (Sigma Chemical Co., 
USA) supplemented with HAT Media Supplement (Sig-
ma Chemicals, USA), penicillin G sodium sulphate (100 
units/ml), streptomycin sulphate (100 μg/ml), amphoter-
icin B (0.25 μg/ml) and 10 % FBS. Cells were grown in 
humidified atmosphere of 5 % CO2/ 95 % air at 37 °C 
and were subcultured every 3–4 days as described previ-
ously (Olszanecki et al., 2006).
The cells were seeded in wells of six-well plates 
(1 × 106 per well) and serum-starved (appropriate medium 
containing one-tenth of the normal FBS concentration 
for 6 hours before experiment). The cells were incubated 
with Bk (10 nM, Sigma Chemicals, USA) for up to 24 
hours. Supernatants were collected either at time „0” 
(immediately after administration of Bk) or at indicated 
time points and frozen at –70 °C. 
Measurement of bradykinin peptide concentration 
by LC-MS. Frozen supernatants from tissue samples 
and cell culture samples were thawed at room tempera-
ture and injected onto a chromatographic column. Sepa-
ration of bradykinins was performed on a reversed-phase, 
high performance liquid chromatography (HPLC) system 
Ultimate 3000 (Dionex, USA) with a PepMap 100 C18 
column (150 mm × 1 mm, 5 µm particle size) in com-
bination with an appropriate guard column (5 mm × 1 
mm; 5 µm particle size) (Dionex, USA). The optimized 
mobile phase solvents were: 5 % acetonitrile in a buffer 
of 4 mM ammonium formate with 4 mM formic acid 
(phase A) and 90 % acetonitrile in same buffer (phase 
B). Bk and its metabolites were separated at a flow rate 
of 0.045 ml/min with a linear gradient of B in A.
Mass spectrometric detection was performed using an 
LCQ ion-trap mass spectrometer (Finnigan, San Jose, 
USA) equipped with an ESI source (electrospray). High 
purity nitrogen used as a sheath gas was generated with 
a Claind nitrogen generator. All experiments were carried 
out in the positive ion mode. Bradykinins solutions were 
infused directly into the mass spectrometer at 3 µl/min. 
The main working parameters of the mass spectrometer 
were as follows: nitrogen (sheath gas) flow rate 65 arb, 
ion spray voltage 5 kV, capillary temperature 200 °C, 
capillary voltage 46 V, tube lens offset 40 V. For opti-
mization of ESI conditions the scan mode in the range 
100–2000 Da was used. For bradykinin detection, se-
lected ion monitoring (SIM) mode was used with total 
microscans = 1 and maximum inject time of 500 ms. 
Scanned mass range was set at 530–760 Da. LCQ data 
were analyzed by Xcalibur Software, version 1.0 (Finni-
gan). Concentrations of bradykinins were calculated us-
ing standard calibration curves constructed by linear re-
gression analysis of peak area versus bradykinin concen-
tration. The calibration curves were prepared for each 
peptide examined — Bk, Bk-(1–7) and Bk-(1–5) — at a 
concentration range of 20 pM to 100 nM. 
Chemicals. Bradykinin (Bk), Bk-(1–7) and Bk-(1–5) 
were purchased from Sigma Chemicals (USA). Formic 
acid (99 %) (Riedel de Haen, Germany), acetonitrile 
(Baker), ammonium formate (Fluka) were HPLC grade. 
Deionized water was obtained using a MilliPore (MilliQ) 
system.
Statistics. Concentrations of bradykinin peptides were 
expressed in pmol/mg dry tissue and in pM (cell cul-
ture). All values in the figures and text are expressed as 
mean ±S.E. of n = 15 observations. Concentrations of 
the analytes studied were compared using non-paramet-
ric Wilcoxon’s test. A P value less than 0.05 was consid-
ered to be statistically significant. 
RESULTS AND DISCUSSION
Measurement of concentrations of Bk and its 
metabolites
The LC-ESI-MS method proved to be a valuable tool 
for assessment of exogenous Bk metabolism ex vivo, in 
organ-bath of tissue fragments excised from rats, and 
in vitro in a culture of endothelial cells. The separation 
conditions allowed easy determination of Bk and its two 
main metabolites in both types of samples (Fig. 2). The 
molecular mass of Bk, Bk-(1–7) and Bk-(1–5) are 1059 
Da, 756 Da and 572 Da, respectively (Table 1). The ions 
monitored in the samples by ESI-MS in the SIM mode 
are presented in Table 1. The detection limit for Bk, Bk-
(1–5) and Bk-(1–7) was 0.1 pM. 
Bradykinin degradation by cultured endothelial cells
Ea.hy926 endothelial cells were able to metabolize 
exogenous Bk both to  the Bk-(1–7) and Bk-(1–5) pep-
tides. The proportion of these metabolites changed over 
the time of incubation with Bk: in the beginning, in the 
presence of excess substrate, much more Bk-(1–7) than 
Bk-(1–5) was produced. This is in agreement with our 
previous results on angiotensin I metabolism, showing 
that neutral endopeptidase (NEP) and/or ACE2 over-
Figure 1. Main bradykinin degradation pathways
ACE, angiotensin converting enzyme; ACE2, angiotensin convert-
ing enzyme-related carboxypeptidase; APP, aminopeptidase P; 
CPN, carboxypeptidase; DPP IV, dipeptidylpeptidase IV; ECE, en-
dothelin converting enzyme; NEP, neprilysin, membrane-bound 
neutral endopeptidase; POP, prolyloligopeptidase
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whelm ACE activity in these cells (Bujak-Gizycka et al., 
2007). Importantly, Bk-(1–7) may serve as a substrate 
only for ACE (Fig. 1), so as expected, starting from the 
4th hour of incubation, Bk-(1–5) became the prevalent 
metabolite of Bk slowly accumulating in culture medium 
(concentrations after 24 h: 233.1 pM of Bk-(1–5) vs. 
21.5 pM of Bk-(1–7)). Thus, our data suggest sequen-
tial degradation of Bk in cell culture: first to Bk-(1–7) 
and subsequently to Bk-(1–5). It has been demonstrated 
that in primary endothelial cell cultures activities of ACE 
and NEP may vary and strongly depend on the vascular 
origin (cells from pulmonary artery express much more 
ACE than from other vascular beds) and time of culti-
vation (ACE in HUVEC is downregulated with subse-
quent passages) (Baudin et al., 1997; Balyasnikova et al., 
1998). Our study confirms that the LC-MS method is a 
valuable tool for assessment of kinin metabolism in cell 
culture setting. 
Bradykinin metabolism in aorta of hypertensive rats
Incubation of aorta of WKY and SHR rats with exog-
enous Bk for 15 min resulted in the generation of a roughly 
equimolar mixture of Bk-(1–5) and Bk-(1–7) (at that time 
the substrate was still present in excess in incubation buff-
er). Importantly, the degrada-
tion of bradykinin and genera-
tion of both metabolites were 
significantly higher in the aorta 
of SHR rats than in the WKY 
controls (Table 2). Accord-
ingly, the effects of ACE and 
NEP inhibitors were more pro-
nounced in SHR: perindoprilat 
inhibited Bk-(1–5) formation 
by 49 % and 76 % in WKY 
and SHR rats, respectively, and tiorphan tended to decrease 
formation of Bk-(1–5) in both groups of animals, but only 
in SHR its action reached statistical significance (Table 2). 
Although some studies have shown higher ACE activity 
in spontaneously hypertensive rats (Sivieri, Jr. et al., 2007), 
previous reports, focused mainly on Bk metabolism in the 
plasma, did not reveal any differences between WKY and 
SHR groups (Dendorfer et al., 2001). Here, differences in 
the rate of Bk degradation directly in the artery wall are de-
montrated between WKY and SHR rats for the first time. 
Our results demonstrated that even in relatively early hyper-
tension (in 4-month old SHR rats) decomposition of Bk by 
the vessel wall is enhanced. It is widely recognized that Bk 
is one of the most potent stimulators of endothelial cells 
to release nitric oxide and prostacyclin (Mombouli & Van-
houtte, 1995; Gryglewski et al., 2002). Whether enhanced 
Bk degradation in hypertensive rats may contribute to the 
endothelial dysfunction seen in these animals (Bernatova 
et al., 2009) is still a matter of controversy. Interestingly, 
young hypertensive rats seem not to suffer from lower lev-
els of Bk in tissues — on the contrary, Campbell and cow-
orkers (1995) observed elevated levels of Bk as well as its 
metabolites (reflecting over activation of kalikrein) in tissues 
of these animals. There are limited data concerning similar 
Table 1. Molecular characteristics of bradykinin and its metabolites
Peptide name Amino-acid sequence Molecular mass [g/mol]
Monitored 
ion (m/z) Ion charge (z)
Bradykinin R-P-P-G-F-S-P-F-R 1060.22 531 2
Bradykinin-(1–7) R-P-P-G-F-S-P 756.86 757 1
Bradykinin-(1–5) R-P-P-G-F 572.66 573 1
Figure 2. Chromatograms of Bk and its main metabolites
(A) Mixture of standards; (B) in EA.hy926 cell culture (4 h of incubation with 10 nM Bk); (C) in aorta of WKY rats (15 min of incubation 
with 100 nM Bk). 
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changes in Bk metabolism in humans. Notably, some au-
thors showed that concentration of Bk-(1–5) in human cir-
culation system was significantly higher in hypertensive pa-
tients (Murphey et al., 2004). It is tempting to speculate that 
because of the more intense Bk degradation, prehyperten-
sive and hypertensive patients could benefit more from the 
“bradykinin-sparing” effect of ACE and NEP inhibitors. 
In contrast to the generation of Bk-(1–5), which was 
mainly ACE-dependent, our study confirmed an involve-
ment of numerous proteases in the formation of Bk-
(1–7) in the rat aorta: neither ACE nor NEP inhibition 
influenced significantly formation of Bk-(1–7) in the 
SHR or WKY rats (Table 2). This is in agreement with 
previous reports, identifying Bk-(1–5) as the main prod-
uct of direct Bk degradation by ACE, and direct and/
or indirect involvement of ECE, CPN, POP and ACE2 
in tissue formation of Bk-(1–7) (Dendorfer et al., 2001). 
Clearly, a thorough analysis of Bk degradation pathways 
would require not only a pharmacological approach, but 
also estimation of particular protease activity in aortic 
tissue. Our study opens the question of differences be-
tween WKY and SHR rats regarding Bk metabolism at 
the molecular level for further research.
In comparison to angiotensins, studies exploring the 
bioactivities of Bk metabolites are limited. It has been 
shown that Bk-(1–5) (according to amino-acids sequence 
sometimes presented as RPPGF; thrombostatin) can 
inhibit thrombin-induced platelet activation by block-
ing protease-activated receptor type 1 (PAR-1), thereby 
preventing occlusion in a canine coronary thrombosis 
model (Hasan et al., 1996; 1999). There is no data about 
biological activity of Bk-(1–7).
CONCLUSION
Our study shows differences between metabolism of 
bradykinin in young hypertensive and normotensive rats. 
We demonstrated that degradation of Bk to Bk-(1–5) 
and Bk-(1–7) is enhanced in the aorta of hypertensive 
rats probably due to higher ACE activity in these ani-
mals. The functional significance of this finding requires 
further investigation.
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